Cargando…
Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules
BACKGROUND: Haemophilus influenzae serotype b (Hib) conjugate vaccine was introduced in France in 1992 as a 3 + 1 scheme at 2, 3, and 4 months (primary vaccination) with a booster at the age of 16–18 months. The vaccination was simplified in 2013 to a 2 + 1 scheme at 2 and 4 months (primary immuniza...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325224/ https://www.ncbi.nlm.nih.gov/pubmed/34330228 http://dx.doi.org/10.1186/s12879-021-06440-w |
_version_ | 1783731524124803072 |
---|---|
author | Hong, Eva Terrade, Aude Denizon, Mélanie Aouiti-Trabelsi, Myriam Falguières, Michaël Taha, Muhamed-Kheir Deghmane, Ala-Eddine |
author_facet | Hong, Eva Terrade, Aude Denizon, Mélanie Aouiti-Trabelsi, Myriam Falguières, Michaël Taha, Muhamed-Kheir Deghmane, Ala-Eddine |
author_sort | Hong, Eva |
collection | PubMed |
description | BACKGROUND: Haemophilus influenzae serotype b (Hib) conjugate vaccine was introduced in France in 1992 as a 3 + 1 scheme at 2, 3, and 4 months (primary vaccination) with a booster at the age of 16–18 months. The vaccination was simplified in 2013 to a 2 + 1 scheme at 2 and 4 months (primary immunization) and a booster at the age of 11 months. The coverage was 95.4% in France at 24 months in 2017. During the period 2017–2019 the number of Hib invasive infections increased with several cases of vaccine failure. METHODS: The numbers and proportions of Hib invasive isolates during the period 2017–2019 were compared and vaccine failure cases were explored. A seroprevalence study was performed by measuring anti-polyribosyl-ribitol phosphate (PRP) IgG concentrations by ELISA among children < 5 years of age at the time of sampling covering the periods of the 3 + 1 or 2 + 1 schemes of Hib vaccination. A collection of residual 232 sera was tested (group 3 + 1 n = 130) and (group 2 + 1, n = 102) was used. RESULTS: Anti-PRP IgG concentrations were significantly higher in toddlers of 2 years (median 2.9 μg/ml) in the 3 + 1 group while these concentrations showed a median of 0.58 μg/ml among children in 2 + 1 group. The proportion of children of 2 years of age who achieved 1 μg/ml threshold (56%) was higher in the 3 + 1 group than that observed in the 2 + 1 group (25%). All the detected cases of vaccine failure received the 2 + 1 scheme and anti-PRP IgG levels were less than 1 μg/ml at the admission. However, these levels increased significantly 1 month after the admission suggesting a secondary immune response to the Hib infection. CONCLUSIONS: The simplification of the vaccination to a 2 + 1 scheme seems to reduce the level of anti PRP IgG. Hib antibodies wane rapidly after the 11 months booster and may not be enough to ensure long term protection. Surveillance of cases and monitoring of titres need to be continued to inform future vaccination policy. |
format | Online Article Text |
id | pubmed-8325224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83252242021-08-02 Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules Hong, Eva Terrade, Aude Denizon, Mélanie Aouiti-Trabelsi, Myriam Falguières, Michaël Taha, Muhamed-Kheir Deghmane, Ala-Eddine BMC Infect Dis Research Article BACKGROUND: Haemophilus influenzae serotype b (Hib) conjugate vaccine was introduced in France in 1992 as a 3 + 1 scheme at 2, 3, and 4 months (primary vaccination) with a booster at the age of 16–18 months. The vaccination was simplified in 2013 to a 2 + 1 scheme at 2 and 4 months (primary immunization) and a booster at the age of 11 months. The coverage was 95.4% in France at 24 months in 2017. During the period 2017–2019 the number of Hib invasive infections increased with several cases of vaccine failure. METHODS: The numbers and proportions of Hib invasive isolates during the period 2017–2019 were compared and vaccine failure cases were explored. A seroprevalence study was performed by measuring anti-polyribosyl-ribitol phosphate (PRP) IgG concentrations by ELISA among children < 5 years of age at the time of sampling covering the periods of the 3 + 1 or 2 + 1 schemes of Hib vaccination. A collection of residual 232 sera was tested (group 3 + 1 n = 130) and (group 2 + 1, n = 102) was used. RESULTS: Anti-PRP IgG concentrations were significantly higher in toddlers of 2 years (median 2.9 μg/ml) in the 3 + 1 group while these concentrations showed a median of 0.58 μg/ml among children in 2 + 1 group. The proportion of children of 2 years of age who achieved 1 μg/ml threshold (56%) was higher in the 3 + 1 group than that observed in the 2 + 1 group (25%). All the detected cases of vaccine failure received the 2 + 1 scheme and anti-PRP IgG levels were less than 1 μg/ml at the admission. However, these levels increased significantly 1 month after the admission suggesting a secondary immune response to the Hib infection. CONCLUSIONS: The simplification of the vaccination to a 2 + 1 scheme seems to reduce the level of anti PRP IgG. Hib antibodies wane rapidly after the 11 months booster and may not be enough to ensure long term protection. Surveillance of cases and monitoring of titres need to be continued to inform future vaccination policy. BioMed Central 2021-07-30 /pmc/articles/PMC8325224/ /pubmed/34330228 http://dx.doi.org/10.1186/s12879-021-06440-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Hong, Eva Terrade, Aude Denizon, Mélanie Aouiti-Trabelsi, Myriam Falguières, Michaël Taha, Muhamed-Kheir Deghmane, Ala-Eddine Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules |
title | Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules |
title_full | Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules |
title_fullStr | Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules |
title_full_unstemmed | Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules |
title_short | Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules |
title_sort | haemophilus influenzae type b (hib) seroprevalence in france: impact of vaccination schedules |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325224/ https://www.ncbi.nlm.nih.gov/pubmed/34330228 http://dx.doi.org/10.1186/s12879-021-06440-w |
work_keys_str_mv | AT hongeva haemophilusinfluenzaetypebhibseroprevalenceinfranceimpactofvaccinationschedules AT terradeaude haemophilusinfluenzaetypebhibseroprevalenceinfranceimpactofvaccinationschedules AT denizonmelanie haemophilusinfluenzaetypebhibseroprevalenceinfranceimpactofvaccinationschedules AT aouititrabelsimyriam haemophilusinfluenzaetypebhibseroprevalenceinfranceimpactofvaccinationschedules AT falguieresmichael haemophilusinfluenzaetypebhibseroprevalenceinfranceimpactofvaccinationschedules AT tahamuhamedkheir haemophilusinfluenzaetypebhibseroprevalenceinfranceimpactofvaccinationschedules AT deghmanealaeddine haemophilusinfluenzaetypebhibseroprevalenceinfranceimpactofvaccinationschedules |